On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $51.48 which represents a decrease of $-1.75 or -3.29% from the prior close of $53.23. The stock opened at $53.14 and ...
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. Shares of Exact ...
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.
Super Micro Computer (NASDAQ: SMCI) fell 10% after its preliminary guidance for quarterly sales trailed estimates. It sees ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback